These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11724337)

  • 1. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
    Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
    Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
    Niewolik D; Vojtesek B; Kovarik J
    Oncogene; 1995 Mar; 10(5):881-90. PubMed ID: 7898929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geldanamycin selectively destabilizes and conformationally alters mutated p53.
    Blagosklonny MV; Toretsky J; Neckers L
    Oncogene; 1995 Sep; 11(5):933-9. PubMed ID: 7675452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53.
    Sugikawa E; Yazaki N; Tsunoda S; Nakanishi N; Ohashi M
    Biochem Biophys Res Commun; 1999 Aug; 261(2):256-63. PubMed ID: 10425175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of the transcription activation function to mutant p53 in human cancer cells.
    Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
    Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 DNA binding can be modulated by factors that alter the conformational equilibrium.
    McLure KG; Lee PW
    EMBO J; 1999 Feb; 18(3):763-70. PubMed ID: 9927436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence-specific interaction of a conformational domain of p53 with DNA.
    Srinivasan R; Roth JA; Maxwell SA
    Cancer Res; 1993 Nov; 53(22):5361-4. PubMed ID: 8221671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
    Tarunina M; Jenkins JR
    Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro analysis of the dominant negative effect of p53 mutants.
    Chène P
    J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53.
    Kim E; Albrechtsen N; Deppert W
    Oncogene; 1997 Aug; 15(7):857-69. PubMed ID: 9266973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dominant negative activity of mutated p53 proteins].
    Dridi W; Krabchi K; Gadji M; Lavoie J; Bronsard M; Fetni R; Drouin R
    Med Sci (Paris); 2006 Mar; 22(3):301-7. PubMed ID: 16527213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
    Roemer K
    Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
    Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
    Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A PAb240+ conformation of wild type p53 binds DNA.
    McLure KG; Lee PW
    Oncogene; 1996 Sep; 13(6):1297-303. PubMed ID: 8808704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.